The Cell Medica Approach

Cell Medica is committed to transforming patients’ lives through developing the significant therapeutic potential of cellular immunotherapy for the treatment of cancer. We are advancing innovative cell-based therapies using proprietary technology platforms incorporating chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs).

Our CAR-modified T cell products are being developed in collaboration with Baylor College of Medicine and University of North Carolina. Cell Medica’s differentiated approach utilises NKT cells (a subset of T cells) engineered to express IL-15 to maintain anti-cancer potency within the immunosuppressive tumour micro-environment. We are developing both autologous and allogeneic (off-the-shelf) products using the CAR-NKT cell technology.

In the field of engineered TCRs, we are working with University College London, to develop the Dominant TCR technology to improve the potency of TCR-modified T cells while maintaining the safety profile.  Our product portfolio also includes baltaleucel-T (EBV-specific T cells) for the treatment of lymphomas associated with the Epstein Barr virus.